Mer­ck pens pact with Pearl Bio for new bi­o­log­ics in can­cer

Mer­ck is team­ing up with a Khosla Ven­tures-backed biotech in a pack­age that could be worth as much as $1 bil­lion to cre­ate new bi­o­log­ics for can­cer.

Pearl Bio is still in the seed stage and is ad­vised by George Church, and will get an undis­closed up­front from Mer­ck. Cam­bridge, MA-based Pearl Bio could al­so re­ceive roy­al­ties on sales if the pact leads to ap­proved drugs, the com­pa­nies said Tues­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER